Judge Blocks Par Pharma's Generic Treximet

Law360, New York (April 15, 2011, 1:43 PM EDT) -- A Texas federal judge on Thursday barred Par Pharmaceutical Cos. Inc. from selling a generic version of Pozen Inc. migraine treatment Treximet in the U.S. until a patent infringement battle over the drug is resolved.

Judge Leonard Davis of the U.S. District Court for the Eastern District of Texas found that Pozen had sufficiently shown that it was likely to succeed against Par on the merits of its infringement claim of U.S. Patent Number 6,586,458, justifying a preliminary injunction.

“Defendants’ invalidity and unenforceability claims fail to...
To view the full article, register now.